Congenital Myotonic Dystrophy Trial Now Recruiting
The NMD4C is excited to share that an international randomized, multicenter, double-blind, placebo-controlled, phase 2/3 clinical trial testing the safety and efficacy of Tideglusib in Congenital Myotonic Dystrophy (CDM) patients aged 6-16 has begun recruiting. This is the first CDM trial to take place in Canada, even though CDM is one of the more common neuromuscular diseases in Canada, affecting more than one in 50,000 live births. The two Canadian sites are the Children’s Hospital London Health Sciences Centre (LHSC) in London, ON and the Children’s Hospital of Eastern Ontario (CHEO) in Ottawa, ON, with Drs. Craig Campbell and Hanns Lochmüller as Principal Investigators.
Both the London and Ottawa sites are open for recruitment; contact information for both sites is located below. If you would like to learn more about the eligibility criteria and for further information, please visit the ClinicalTrials.gov site to find detailed information!
LHSC site: Rhiannon Hicks, rhiannon.hicks@lhsc.on.ca, (519)-685-8441.
CHEO site: Emilie Hill-Smith, EHillSmith@cheo.on.ca, 613-737-7600 ext. 4014.
Read next...
You Can Now Find NMD4C on Bluesky
We’re moving to Bluesky! The NMD4C will now share updates on Bluesky instead of X. Please consider following us at @nmd4c.ca to stay connected!
CIHR Funds Interdisciplinary Project to Study SBMA in Indigenous Peoples of the Prairie Provinces
The NMD4C is excited to share that network investigators have been awarded funding from the CIHR for an Interdisciplinary Spinal-bulbar muscular atrophy study in Indigenous peoples of the prairie provinces, addressing the community needs, and developing clinical knowledge and therapies.
NMD4C Presents the 2025 Early Career Award Recipients
We are excited to announce the recipients of the 2025 NMD4C Early Career Awards! This is the third year of our annual award program, celebrating excellence and contribution to the neuromuscular field from early career investigators across both clinical and basic science streams.
Muscular Dystrophy Canada Launches Initiative to Improve Genetic Testing Access for Myotonic Dystrophy
Muscular Dystrophy Canada is thrilled to launch an innovative initiative designed to tackle the diagnostic hurdles experienced by individuals with myotonic dystrophy.
New Content Available in LEARNMD
LEARNMD is the NMD4C’s online educational platform, offering talks and sessions on a wide range of neuromuscular topics presented by leading clinical and scientific experts worldwide. We’re excited to share what’s new on LEARNMD in February 2025!
Quebec Network Réseau Québécoise de l’Amyotrophie Spinale Joins NMD4C as Community of Practice Sub-Group
We are thrilled to announce that the RQAS, a network uniting rehabilitation clinicians across Quebec to advance the care of people with Spinal Muscular Atrophy has officially become a sub-group Community of Practice of the NMD4C